MX2019014831A - Metodos para el tratamiento de la hiperlipidemia en pacientes diabeticos administrando un inhibidor de pcsk9. - Google Patents
Metodos para el tratamiento de la hiperlipidemia en pacientes diabeticos administrando un inhibidor de pcsk9.Info
- Publication number
- MX2019014831A MX2019014831A MX2019014831A MX2019014831A MX2019014831A MX 2019014831 A MX2019014831 A MX 2019014831A MX 2019014831 A MX2019014831 A MX 2019014831A MX 2019014831 A MX2019014831 A MX 2019014831A MX 2019014831 A MX2019014831 A MX 2019014831A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- administering
- diabetic patients
- pcsk9 inhibitor
- treating hyperlipidemia
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 208000031226 Hyperlipidaemia Diseases 0.000 title 1
- 229940122392 PCSK9 inhibitor Drugs 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 4
- 102000004877 Insulin Human genes 0.000 abstract 2
- 108090001061 Insulin Proteins 0.000 abstract 2
- 229940125396 insulin Drugs 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21062—Subtilisin (3.4.21.62)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762517672P | 2017-06-09 | 2017-06-09 | |
| US201762532162P | 2017-07-13 | 2017-07-13 | |
| EP18305565 | 2018-05-04 | ||
| PCT/IB2018/054182 WO2018225041A1 (en) | 2017-06-09 | 2018-06-09 | Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019014831A true MX2019014831A (es) | 2020-02-13 |
Family
ID=62815099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019014831A MX2019014831A (es) | 2017-06-09 | 2018-06-09 | Metodos para el tratamiento de la hiperlipidemia en pacientes diabeticos administrando un inhibidor de pcsk9. |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP3634469A1 (enExample) |
| JP (2) | JP2020522544A (enExample) |
| KR (1) | KR20200026826A (enExample) |
| CN (1) | CN110913889A (enExample) |
| AU (1) | AU2018280567A1 (enExample) |
| CA (1) | CA3066317A1 (enExample) |
| IL (2) | IL271212B2 (enExample) |
| MX (1) | MX2019014831A (enExample) |
| TW (2) | TW201904608A (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| MX347602B (es) | 2011-01-28 | 2017-05-03 | Sanofi Biotechnology | Composiciones farmaceuticas que comprenden anticuerpos humanos frente a pcsk9. |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| US10772956B2 (en) | 2015-08-18 | 2020-09-15 | Regeneron Pharmaceuticals, Inc. | Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab |
| CN113876956B (zh) * | 2020-07-01 | 2023-07-04 | 陈敏 | Pcsk9抑制剂在制备促进皮肤色素生成产品中的应用 |
| CN114525258A (zh) * | 2020-10-30 | 2022-05-24 | 未来智人再生医学研究院(广州)有限公司 | 一种表达pcsk9阻断物的多能干细胞或其衍生物及应用 |
| CN118076736A (zh) * | 2021-09-30 | 2024-05-24 | 北京安龙生物医药有限公司 | 用于治疗与pcsk9相关疾病的靶向寡核苷酸 |
| WO2023104051A1 (zh) * | 2021-12-07 | 2023-06-15 | 广州嘉越医药科技有限公司 | 吲哚取代四氢异喹啉类化合物与他汀类化合物的联合应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3672B1 (ar) * | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| US20150283236A1 (en) * | 2014-03-17 | 2015-10-08 | Marie Baccara-Dinet | Methods for treating subjects with primary hypercholesterolemia that is not adequately controlled |
| EP3753575A1 (en) * | 2014-07-16 | 2020-12-23 | Sanofi Biotechnology | Methods for treating high cardiovascular risk patients with hypercholesterolemia using inhibitors of pcsk9 |
| CA2955294A1 (en) * | 2014-07-16 | 2016-01-21 | Sanofi Biotechnology | Methods for treating patients with heterozygous familial hypercholesterolemia (hefh) |
| US10772956B2 (en) * | 2015-08-18 | 2020-09-15 | Regeneron Pharmaceuticals, Inc. | Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab |
-
2018
- 2018-06-08 TW TW107119851A patent/TW201904608A/zh unknown
- 2018-06-08 TW TW111142924A patent/TW202310872A/zh unknown
- 2018-06-09 KR KR1020197038159A patent/KR20200026826A/ko not_active Ceased
- 2018-06-09 JP JP2019567608A patent/JP2020522544A/ja active Pending
- 2018-06-09 EP EP18737034.1A patent/EP3634469A1/en not_active Withdrawn
- 2018-06-09 CN CN201880037888.2A patent/CN110913889A/zh not_active Withdrawn
- 2018-06-09 CA CA3066317A patent/CA3066317A1/en active Pending
- 2018-06-09 IL IL271212A patent/IL271212B2/en unknown
- 2018-06-09 MX MX2019014831A patent/MX2019014831A/es unknown
- 2018-06-09 AU AU2018280567A patent/AU2018280567A1/en not_active Abandoned
- 2018-06-09 IL IL314423A patent/IL314423A/en unknown
-
2023
- 2023-07-07 JP JP2023111915A patent/JP2023123842A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019144346A (ru) | 2021-07-09 |
| IL314423A (en) | 2024-09-01 |
| IL271212A (en) | 2020-01-30 |
| CN110913889A (zh) | 2020-03-24 |
| IL271212B1 (en) | 2024-08-01 |
| TW202310872A (zh) | 2023-03-16 |
| AU2018280567A1 (en) | 2020-01-23 |
| EP3634469A1 (en) | 2020-04-15 |
| KR20200026826A (ko) | 2020-03-11 |
| RU2019144346A3 (enExample) | 2021-10-13 |
| JP2020522544A (ja) | 2020-07-30 |
| CA3066317A1 (en) | 2018-12-13 |
| IL271212B2 (en) | 2024-12-01 |
| TW201904608A (zh) | 2019-02-01 |
| JP2023123842A (ja) | 2023-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019014831A (es) | Metodos para el tratamiento de la hiperlipidemia en pacientes diabeticos administrando un inhibidor de pcsk9. | |
| PH12019502484A1 (en) | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| UA117570C2 (uk) | Спосіб лікування діабету або діабету, спричиненого ожирінням, або ускладнень при діабеті | |
| MX2009012343A (es) | Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello. | |
| MX381780B (es) | Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo. | |
| MY198928A (en) | B7-h3 antibody, antigen-binding fragment thereof and medical use thereof | |
| EP4424324A3 (en) | Dosage and administration of anti-c5 antibodies for treatment of patients with membranoproliferative glomerulonephritis | |
| CY1111595T1 (el) | Τροποποιηση της θεραπειας με πιρφενιδονη για ασθενεις με μη φυσιολογικη ηπατικη λειτουργια | |
| MX2010006823A (es) | Metodos para el tratamiento de la gota. | |
| CY1118616T1 (el) | Λιξισενατιδη ως προσθετη θεραπεια σε βασικη ινσουλινη σε διαβητη τυπου 2 | |
| FI20135152A7 (fi) | Farmaseuttinen yhdistelmäkoostumus ja menetelmiä diabeteksen ja metabolisten sairauksien hoidossa | |
| EA201490378A1 (ru) | ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β | |
| MX2019014375A (es) | Anticuerpo anti-cd40, fragmento de union a antigeno del mismo, y uso medico del mismo. | |
| MX2021004994A (es) | Dosificacion subcutanea y administracion de anticuerpos anti-c5 para el tratamiento de la hemoglobinuria paroxistica nocturna (pnh). | |
| MX2022008471A (es) | Anticuerpo anti-angptl3 y uso del mismo. | |
| WO2018116267A3 (en) | Methods of treatment with anti-factor xi/xia antibodies | |
| EA202091974A1 (ru) | Связывающие bcma антитела и их применение | |
| BR112016023011A2 (pt) | tratamento de câncer gástrico | |
| MX2024005430A (es) | Composiciones, formas farmaceuticas y metodos de anticuerpos anti-tau. | |
| MX2025006068A (es) | Proteina de union cldn18.2/4-1bb y su uso medico | |
| MX2022006812A (es) | Metodos para tratar epoc mediante la administracion de un antagonista de il-33. | |
| MY200701A (en) | Method of averting opioid addiction | |
| PH12020550066A1 (en) | METHOD FOR TREATING TNFa-RELATED DISEASE | |
| EA202092978A3 (ru) | Фармацевтическая композиция для парентерального капельного введения | |
| RU2018147275A (ru) | Способ лечения сахарного диабета 2 типа у больных со стеатогепатитом |